NCT07167069Completed
India HIV-CervCa Project
Comparison of Treatment Adherence and Toxicities of HIV Positive Patients Versus HIV Negative Cervical Cancer Patients in India
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
The investigators propose to prospectively study the difference in treatment (CTRT) completion and toxicities between HIV positive and HIV negative women in India with locally advanced cervical cancer receiving CTRT.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 180 (actual)
- First submitted
- 19 Aug 2025
- Start date
- 9 Feb 2021
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- HIV, Cervical cancer
- NCT number
- NCT07167069
What you commit to
- Study type: Observational
- Participants enrolled: 180
- From 9 Feb 2021 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with active tuberculosis
Who the study is looking for
- patients with newly biopsy proven squamous carcinoma or adenocarcinoma of the uterine cervix, FIGO stage IB2-IIIB in whom curative CTRT is planned
- Karnofsky performance status ≥ 70
- Patients with lower paraortic lymph nodes (below the level of L2 vertebra)
- patients diagnosed with cervical cancer whom also HIV positive or HIV negative
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tata Memorial Hospital Coordinator of this site? Confirm its status | Mumbai | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.